Figure 5A,,
Effect of MxiN on Spa47 activity,,
,,
Spa47 Trimer,,
[MxiN] (uM),Average (sec-1),Stdev (sec-1)
0,0.88,0.05
0.1125,0.85,0.04
0.225,0.79,0.08
0.45,0.66,0.03
0.675,0.63,0.11
0.9,0.63,0.14
1.35,0.59,0.07
2.025,0.52,0.1
2.7,0.48,0.08
4.5,0.44,0.05
6.75,0.43,0.05
,,
Spa47 Monomer,,
[MxiN] (uM),Average (sec-1),Stdev (sec-1)
0,0.25,0.04
0.225,0.22,0.03
0.45,0.23,0.01
0.9,0.27,0.01
1.35,0.33,0.02
1.8,0.37,0.03
2.7,0.42,0.06
4.05,0.48,0.06
5.4,0.49,0.07
,,
Spa47 Delta 1-6 ,,
[MxiN] (uM),Average (sec-1),Stdev (sec-1)
0,0.12,0.01
1.35,0.12,0.01
2.7,0.12,0.01
4.5,0.11,0.02
6.75,0.1,0.01
,,
,,
Figure 5B,,
Effect of MxiN on Spa47 substrate concentration dependence ,,
,,
Spa47 Trimer,,
[ATP] (uM),Average (umol ADP/min/mg Spa47) ,Stdev (umol ADP/min/mg Spa47)
25,0.17,0.01
50,0.39,0.03
100,0.4,0.03
250,0.71,0.06
500,0.94,0.03
750,0.92,0.02
1000,0.85,0.03
,,
Spa47 Trimer + MxiN,,
[ATP] (uM),Average (umol ADP/min/mg Spa47) ,Stdev (umol ADP/min/mg Spa47)
25,0.14,0
50,0.19,0.01
100,0.25,0.02
250,0.45,0.04
500,0.48,0.03
750,0.55,0.02
1000,0.55,0.06
,,
Spa47 Monomer,,
[ATP] (uM),Average (umol ADP/min/mg Spa47) ,Stdev (umol ADP/min/mg Spa47)
25,0.03,0
50,0.06,0.01
100,0.09,0
250,0.16,0.04
500,0.2,0.02
1000,0.23,0.01
,,
Spa47 Monomer + MxiN,,
[ATP] (uM),Average (umol ADP/min/mg Spa47) ,Stdev (umol ADP/min/mg Spa47)
25,0.07,0
50,0.11,0.01
100,0.16,0
250,0.3,0.02
500,0.32,0.01
1000,0.45,0